PCS-话题@MedSci

#PCS#

107篇内容 | 2999人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1685578, encodeId=895516855e8b8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Circulation：血清PCSK9浓度或可作为心血管事件的预测因素, objectType=article, longId=65650, objectId=ce36656504b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce36656504b, replyNumber=0, likeNumber=73, createdTime=2016-09-08, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce36656504b, moduleTitle=Circulation：血清PCSK9浓度或可作为心血管事件的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce36656504b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685580, encodeId=6ca516855806f, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, objectType=article, longId=71850, objectId=e5a0e1850d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a0e1850d9, replyNumber=0, likeNumber=48, createdTime=2016-07-09, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a0e1850d9, moduleTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a0e1850d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685570, encodeId=5e4916855e0bb, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, objectType=article, longId=45584, objectId=a925455845d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a925455845d, replyNumber=0, likeNumber=50, createdTime=2015-12-17, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a925455845d, moduleTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a925455845d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685574, encodeId=d22e16855e4f8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=新一代降脂单抗药PCSK9呼之欲出, objectType=article, longId=52297, objectId=a02d5229e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02d5229e21, replyNumber=0, likeNumber=66, createdTime=2016-03-03, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02d5229e21, moduleTitle=新一代降脂单抗药PCSK9呼之欲出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02d5229e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685568, encodeId=15d116855685d, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口, objectType=article, longId=43719, objectId=2cb743e1941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb743e1941, replyNumber=0, likeNumber=57, createdTime=2015-01-21, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb743e1941, moduleTitle=罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb743e1941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685575, encodeId=8c3316855e5e2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=FDA批准新型胆固醇药物（PCSK9抑制剂）, objectType=article, longId=53807, objectId=f22b5380e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f22b5380e9b, replyNumber=0, likeNumber=76, createdTime=2016-03-15, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f22b5380e9b, moduleTitle=FDA批准新型胆固醇药物（PCSK9抑制剂）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f22b5380e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685576, encodeId=351a16855e691, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=ETC-1002降低胆固醇比PCSK9有优势, objectType=article, longId=54267, objectId=edbb5426e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edbb5426e5b, replyNumber=0, likeNumber=94, createdTime=2016-06-18, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edbb5426e5b, moduleTitle=ETC-1002降低胆固醇比PCSK9有优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edbb5426e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685571, encodeId=0f3c16855e1fe, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=多专家解析：降脂新药PCSK9抑制剂炙手可热, objectType=article, longId=46065, objectId=8c9946065b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9946065b4, replyNumber=0, likeNumber=69, createdTime=2015-09-13, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9946065b4, moduleTitle=多专家解析：降脂新药PCSK9抑制剂炙手可热, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9946065b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, objectType=article, longId=42968, objectId=df2042968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2042968c5, replyNumber=0, likeNumber=70, createdTime=2015-03-25, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2042968c5, moduleTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2042968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685569, encodeId=93521685569fc, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, objectType=article, longId=43795, objectId=a88243e95ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a88243e95ba, replyNumber=0, likeNumber=56, createdTime=2014-12-29, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a88243e95ba, moduleTitle=PCSK9抑制剂竞争白热化各大医药巨头抢占市场, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a88243e95ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685572, encodeId=68d616855e2ff, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, objectType=article, longId=49563, objectId=032749563aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032749563aa, replyNumber=0, likeNumber=110, createdTime=2016-03-31, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032749563aa, moduleTitle=NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032749563aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685573, encodeId=c69616855e306, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, objectType=article, longId=49564, objectId=fcff495646e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcff495646e, replyNumber=0, likeNumber=70, createdTime=2016-03-09, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcff495646e, moduleTitle=NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcff495646e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685567, encodeId=ac02168556e2f, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=JCEM：何种PCSK9基因突变类型能降低LDL-C水平？, objectType=article, longId=43081, objectId=854b43081da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854b43081da, replyNumber=0, likeNumber=76, createdTime=2015-07-29, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854b43081da, moduleTitle=JCEM：何种PCSK9基因突变类型能降低LDL-C水平？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=854b43081da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685563, encodeId=5bdb16855635e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, objectType=article, longId=38618, objectId=b1903861805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1903861805, replyNumber=0, likeNumber=58, createdTime=2014-08-28, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1903861805, moduleTitle=赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1903861805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685564, encodeId=1e3a16855641b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, objectType=article, longId=39904, objectId=46043990410, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46043990410, replyNumber=0, likeNumber=91, createdTime=2015-03-28, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46043990410, moduleTitle=ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46043990410)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685559, encodeId=61ee16855591e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, objectType=article, longId=32022, objectId=e7cc32022c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cc32022c7, replyNumber=0, likeNumber=78, createdTime=2014-05-23, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cc32022c7, moduleTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cc32022c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685565, encodeId=1adb16855652c, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）, objectType=article, longId=40894, objectId=400c4089478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=400c4089478, replyNumber=0, likeNumber=75, createdTime=2015-04-18, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=400c4089478, moduleTitle=Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=400c4089478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685556, encodeId=bc40168555647, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Lancet：RNAi基因治疗新药ALN-PCS明显降低患者胆固醇水平（临床I期研究）, objectType=article, longId=25270, objectId=5b5a252e019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b5a252e019, replyNumber=0, likeNumber=51, createdTime=2014-04-18, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b5a252e019, moduleTitle=Lancet：RNAi基因治疗新药ALN-PCS明显降低患者胆固醇水平（临床I期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b5a252e019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685558, encodeId=1cc61685558a2, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, objectType=article, longId=31688, objectId=117b31688b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117b31688b0, replyNumber=0, likeNumber=76, createdTime=2015-02-05, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117b31688b0, moduleTitle=FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117b31688b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685561, encodeId=b7d7168556130, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=刘梅林：PCSK9单克隆抗体“不负众望”, objectType=article, longId=32767, objectId=75e332e67bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e332e67bb, replyNumber=0, likeNumber=129, createdTime=2014-07-20, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e332e67bb, moduleTitle=刘梅林：PCSK9单克隆抗体“不负众望”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e332e67bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PCS

2020-05-29

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Circulation：血清PCSK9浓度或可作为心血管事件的预测因素

2016-09-08

Tamikia (审核中...)

前往app查看评论内容

#PCS#

辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功

2016-07-09

Tamikia (审核中...)

前往app查看评论内容

#PCS#

PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物

2015-12-17

Tamikia (审核中...)

前往app查看评论内容

#PCS#

新一代降脂单抗药PCSK9呼之欲出

2016-03-03

Tamikia (审核中...)

前往app查看评论内容

#PCS#

罕见病领域将成为PCSK9抑制剂实现重磅潜力的突破口

2015-01-21

Tamikia (审核中...)

前往app查看评论内容

#PCS#

FDA批准新型胆固醇药物（PCSK9抑制剂）

2016-03-15

Tamikia (审核中...)

前往app查看评论内容

#PCS#

ETC-1002降低胆固醇比PCSK9有优势

2016-06-18

Tamikia (审核中...)

前往app查看评论内容

#PCS#

多专家解析：降脂新药PCSK9抑制剂炙手可热

2015-09-13

Tamikia (审核中...)

前往app查看评论内容

#PCS#

赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia

2015-03-25

Tamikia (审核中...)

前往app查看评论内容

#PCS#

PCSK9抑制剂竞争白热化各大医药巨头抢占市场

2014-12-29

Tamikia (审核中...)

前往app查看评论内容

#PCS#

NEJM：PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件（OSLER研究）

2016-03-31

Tamikia (审核中...)

前往app查看评论内容

#PCS#

NEJM：PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平

2016-03-09

Tamikia (审核中...)

前往app查看评论内容

#PCS#

JCEM：何种PCSK9基因突变类型能降低LDL-C水平？

2015-07-29

Tamikia (审核中...)

前往app查看评论内容

#PCS#

赛诺菲PCSK9抑制剂alirocumab 9个III期均达主要疗效终点

2014-08-28

Tamikia (审核中...)

前往app查看评论内容

#PCS#

ESC 2014 ：国内外专家点评PCSK9抑制剂远期效果仍待验证

2015-03-28

Tamikia (审核中...)

前往app查看评论内容

#PCS#

安进PCSK9抑制剂evolocumab III期TESLA达主要终点

2014-05-23

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Lancet：PCSK9单抗evolocumab能显著降低家族性高胆固醇血症患者LDL水平 (TESLA研究和RUTHERFORD-2研究）

2015-04-18

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Lancet：RNAi基因治疗新药ALN-PCS明显降低患者胆固醇水平（临床I期研究）

2014-04-18

Tamikia (审核中...)

前往app查看评论内容

#PCS#

FDA要求赛诺菲评估alirocumab认知风险 PCSK9抑制剂研发难度可能加大

2015-02-05

Tamikia (审核中...)

前往app查看评论内容

#PCS#

刘梅林：PCSK9单克隆抗体“不负众望”

2014-07-20

科室
- - 订阅+
  - 更多科室
工具
服务